Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study P.G. Rose, J. Java, M.A. Morgan, A.A. Secord, J. Kesterson, F.B. Stehman, D.P. Warshal, W.T. Creasman, P. Hanjani, R.T. Morris, L.J. Copeland Gynecologic Oncology Volume 141, Pages 207-208 (June 2016) DOI: 10.1016/j.ygyno.2016.04.534 Copyright © 2015 Terms and Conditions
Fig. 1 Kaplan-Meier Overall Survival by Residual Disease. Gynecologic Oncology 2016 141, 207-208DOI: (10.1016/j.ygyno.2016.04.534) Copyright © 2015 Terms and Conditions